Agnico Eagle Mines Ltd vs Charles River Laboratories Intl. Inc — how do they compare? Agnico Eagle Mines Ltd trades at $186.95 (market cap $92.01B), while Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B). The key difference: Agnico Eagle Mines Ltd is far larger — about 6.8× Charles River Laboratories Intl. Inc's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AEM | CRL | |
|---|---|---|
Market Cap | $92.01B | $13.46B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $282.00 |
52-Week Low | $130.23 | $145.57 |
Enterprise Value | $88.85B | $16.30B |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $180.48, up 0.93% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust fundamentals with a P/E of 15.56, net income margin of 40.44%, and record free cash flow of $6.82B in 2025. Recent news highlights operational strength amid gold price gains, though cost pressures are noted.
Outlook remains positive with a $219.63 price target and 67.7% buy ratings, supported by organic growth plans. Risks include rising production costs and gold price volatility. The stock offers upside potential but faces margin compression headwinds in 2026.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →